Sutent
Product Images NDC 63539-017

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sutent (NDC 63539-017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by U.s. Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Sutent 01)

Chemical structure of the active ingredient in SUTENT, showing a complex organic molecule with fluorinated aromatic rings and multiple functional groups, along with a separate smaller molecule representing tartaric acid.*

FDA Label Image

Figure 1 (Sutent 02)

A Kaplan-Meier survival curve comparing time to tumor progression between SUTENT (N=207) and placebo (N=105). The Y-axis represents time to tumor progression probability (%) and the X-axis represents time in weeks. Median time to progression is 27.3 weeks for SUTENT and 6.4 weeks for placebo, with a hazard ratio of 0.33 (95% CI 0.23, 0.47), p < 0.0001.*

FDA Label Image

Figure 2 (Sutent 03)

A Kaplan-Meier survival curve comparing progression-free survival probability over time (weeks) between SUTENT and IFN-α groups, each with 375 subjects. The chart shows longer median survival for SUTENT (47.3 weeks) versus IFN-α (22.0 weeks), with hazard ratio 0.42 (95% CI, 0.32 to 0.54) and p-value below 0.000001.*

FDA Label Image

Figure 3 (Sutent 04)

A Kaplan-Meier survival curve showing disease-free survival probability (%) over time (years) comparing SUTENT (N=309) and placebo (N=306) groups. The chart includes median survival times, hazard ratio (0.76), confidence interval, p-value, and number of subjects at risk at each time point.*

FDA Label Image

Figure 4 (Sutent 05)

A Kaplan-Meier plot comparing the progression-free survival probability over time (months) between SUTENT (N=86) and placebo (N=85) groups. The graph shows SUTENT has a higher median progression-free survival (10.2 months) compared to placebo (5.4 months). It includes hazard ratio and confidence interval data, as well as the number of subjects at risk at various time points.*

FDA Label Image

Logo (Sutent 06)

FDA Label Image

Logo (Sutent 07)

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

SUTENT (sunitinib malate) 50 mg capsules label by U.S. Pharmaceuticals and Pfizer. The label indicates 14 capsules per package, Rx only, and includes storage instructions, dosage note, and manufacturing location in Singapore. The label is marked as a professional sample and not for sale.*

FDA Label Image

Principal Display Panel (12.5 mg Capsule Bottle Label)

Label for Sutent capsules containing 12.5 mg sunitinib malate, distributed by U.S. Pharmaceuticals and manufactured by Pfizer. The label indicates a quantity of 28 capsules, prescription only, with storage instructions and dosage information. It also states the product is made in Singapore and includes the NDC number 63539-017-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.